Background: Children with chronic kidney disease (CKD) require comprehensive assessments, including medical and quality of life (QoL) evaluations. Few studies have been conducted in developing countries. Methods: This cross-sectional study included 2–18-year-old patients who were categorized into 4 groups: the CKD stage 2–3, stage 4–5, stage 5 with dialysis (D), and kidney transplantation (KT) groups. QoL was measured using the Pediatric Quality of Life Inventory™ (PedsQL™) version 4.0; relationships between different factors and QoL were determined using multivariable linear regression analysis. Results: Eighty-seven patients (mean age: 13.3 (4.1) years) were included. The self-reported total scores were 77.5 (12.5), 78.9 (11.2), 77.4 (16.2), and 76.1 (10.9) in the stage 2–3, stage 4–5, stage 5D and KT groups, respectively. Parent-reported scores showed a weak-to-moderate correlation with self-reported scores (r = 0.12–0.42), with total scores of 71.8 (12.7), 69.5 (14.9), 63.4 (14.8), and 70.8 (18.1) in the stage 2–3, 4–5, 5D and KT groups, respectively. Multivariable linear regression revealed that the parent-reported score in the stage 5D group was 15.92 points lower than that in the stage 2–3 group (p = 0.02); the score in the low maternal education group was 10.13 points lower than that in the high maternal education group (p = 0.04). Conclusions: Parent-reported scores showed weak-to-moderate correlation with self-reported scores. Patients with CKD stage 5D and patients with low maternal education had lower QoL. Regular QoL assessment is recommended for patients with advanced CKD and those with socioeconomic vulnerabilities. Graphical

Background: Accurate glomerular filtration rate estimation (eGFR) is essential for managing pediatric kidney transplant recipients. Given the physiology of pediatric patients receiving adult-donor kidneys, identifying the most appropriate plasma creatinine (PCr)-based formula—pediatric or adult-specific—is crucial. Methods: This cross-sectional study included pediatric kidney transplant recipients (age 1–18 years) who received adult-donor kidneys. We compared agreement thresholds of various pediatric and adult PCr-based GFR equations with CKiD 2012 combined PCr‒cystatin C (PCr-CystC) equation via intraclass correlation coefficients (ICCs), concordance correlation coefficients (CCCs), total deviation index (TDI), P30 performance metric (P30), Bland–Altman plots, and receiver-operating characteristic (ROC) analysis. Correlation between CKiD under 25 (U25) PCr–CystC and reference CKiD 2012 equation was also evaluated. Results: One hundred twenty samples were collected from 23 recipients (mean age = 14.2 ± 3.4 years) and donors (mean age = 31.7 ± 10.0 years). Schwartz–Lyon equation demonstrated the highest performance with the reference (ICC = 0.913, CCC = 0.911, TDI = 14.0 mL/min/1.73 m ² , P30 = 99.2%). U25 (ICC = 0.922, CCC = 0.882, P30 = 93.3%), full age spectrum (FAS)-height (ICC = 0.897, CCC = 0.877, P30 = 96.7%), and Bedside Schwartz equations (ICC = 0.850, CCC = 0.819, P30 = 89.2%) showed comparable performance. Bland–Altman plots revealed proportional bias ( p < 0.05), leading to ROC analysis, which identified eGFR < 70 mL/min/1.73 m ² for Schwartz–Lyon, U25, and FAS-height, and < 60 mL/min/1.73 m ² for Bedside Schwartz as optimal agreement thresholds, beyond which each equation showed increased bias. Subgroup analyses also showed better performance in patients aged 10–18 years. Additionally, U25 PCr-CystC equation showed excellent agreement with the reference (ICC = 0.993, CCC = 0.990, P30 = 100%). Conclusions: Schwartz–Lyon equation demonstrated the highest performance among PCr-based equations with the reference in pediatric kidney transplant recipients, particularly when eGFR was < 70 mL/min/1.73 m ² and in patients aged 10–18 years. U25 PCr-CystC equation showed best overall agreement with the reference and should be preferred where CystC measurement is feasible. Graphical A higher resolution version of the Graphical abstract is available as Supplementary information.

Poststroke anxiety affects rehabilitation outcomes. This study aimed to investigate the prevalence of and factors associated with anxiety among patients with stroke at the 1 year after rehabilitation from 9 tertiary centers. Anxiety, functional score, and quality of life were evaluated by the Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A), modified Barthel Index, and World Health Organization Quality of Life-BREF (WHOQoL-BREF), respectively. This study reveals 20 (11.7%) patients with stroke who developed anxiety, and 18 from 171 patients (10.5%) were new cases of anxiety, which was more than double the rate at discharge (4.7%). Factors related to anxiety were depression (adjusted odds ratio [aOR]: 30.7) and having complications (aOR: 12.48).

Canine hip osteoarthritis (OA) requires multidimensional assessment. This randomized, double-blind, placebo-controlled trial evaluated 4-week treatment with meloxicam, PCSO-524, EAB-277, meloxicam plus PCSO-524, or placebo in 203 client-owned dogs with naturally occurring hip OA. The principal outcome was index-hindlimb peak vertical force (PVF) measured by force-plate gait analysis. Secondary outcomes included PVF responder status, orthopedic assessment score (OAS), Liverpool Osteoarthritis in Dogs (LOAD), Canine Brief Pain Inventory (CBPI), and safety assessments. The primary baseline-adjusted mean PVF analysis did not demonstrate treatment superiority among groups. A secondary responder analysis using an analysis-stage >5%BW PVF threshold showed that meloxicam had a nominally higher Week 4 responder probability than placebo (relative risk = 4.000; 95% confidence interval, 1.223 to 13.079; p = 0.022), interpreted as supportive rather than confirmatory. Within-group score reductions were observed in LOAD and CBPI pain interference for the combination group, LOAD for PCSO-524, and CBPI pain interference for EAB-277. OAS did not change significantly within any group. Between-group differences in LOAD and CBPI changes were not significant. No consistent group-level laboratory safety concern was detected. These findings support multidimensional assessment while emphasizing that secondary results do not establish treatment superiority.